Keywords: Abbott Labs, Third quarter 2010 financial results, Solvay, Meridia
Solvay costs and Meridia withdrawal take heavy toll on Abbott Labs 3rd-qtr 2010 results
Article | 21 October 2010
US health care major Abbott Laboratories (NYSE: ABT) posted disappointing financial results for the third quarter of 2010, saying it earned $891 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
